| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2000 American Heart Association, Inc.
Brief Reviews |
Nitric Oxide Synthase in Atherosclerosis and Vascular Injury
Insights From Experimental Gene Therapy
From the Department of Cardiovascular Medicine (K.M.C.), University of Oxford, John Radcliffe Hospital, Oxford, England, and the Division of Cardiology (H.Q., S.E.G.), Duke University Medical Center, Durham, NC.
Correspondence to Keith M. Channon, MD, MRCP, Department of Cardiovascular Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK OX3 9DU. E-mail keith.channon{at}cardiov.ox.ac.uk
Abstract—Gene therapy aims to intervene in a disease process by transfer and expression of specific genes in a target tissue or organ. Cardiovascular gene therapy in humans remains in its infancy, but in the last decade, experimental gene transfer has emerged as a powerful biological tool to investigate the function of specific genes in vascular disease pathobiology. Nitric oxide synthases, the enzymes that produce nitric oxide, have received considerable attention as potential candidates for vascular gene therapy because nitric oxide has pleiotropic antiatherogenic actions in the vessel wall, and abnormalities in nitric oxide biology are apparent very early in the atherogenic process. In this article, we review the use of nitric oxide synthases in experimental vascular gene therapy and assess the utility of these approaches for investigating the role of nitric oxide in atherosclerosis and their potential for human gene therapy.
Key Words: nitric oxide • atherosclerosis • gene transfer • endothelium • adenovirus
This article has been cited by other articles:
 |
|
 |
|
  H. Suzuki, K. Eguchi, H. Ohtsu, S. Higuchi, S. Dhobale, G. D. Frank, E. D. Motley, and S. Eguchi Activation of Endothelial Nitric Oxide Synthase by the Angiotensin II Type 1 Receptor Endocrinology, December 1, 2006; 147(12): 5914 - 5920. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kawashima and M. Yokoyama Dysfunction of Endothelial Nitric Oxide Synthase and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., June 1, 2004; 24(6): 998 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. G. Drew, N. H. Fidge, G. Gallon-Beaumier, B. E. Kemp, and B. A. Kingwell High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation PNAS, May 4, 2004; 101(18): 6999 - 7004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. von der Thusen, M. L. Fekkes, R. Passier, A.J. van Zonneveld, V. Mainfroid, T. J.C. van Berkel, and E. A.L. Biessen Adenoviral Transfer of Endothelial Nitric Oxide Synthase Attenuates Lesion Formation in a Novel Murine Model of Postangioplasty Restenosis Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 357 - 362. [Abstract] [Full Text]
|
|
|
|
 |
|
 V. Schachinger and A. M. Zeiher Atherogenesis--recent insights into basic mechanisms and their clinical impact Nephrol. Dial. Transplant., December 1, 2002; 17(12): 2055 - 2064. [Full Text] [PDF]
|
|
|
|
|
|
B.S. Wung, J.J. Cheng, S.-K. Shyue, and D.L. Wang NO Modulates Monocyte Chemotactic Protein-1 Expression in Endothelial Cells Under Cyclic Strain Arterioscler. Thromb. Vasc. Biol., December 1, 2001; 21(12): 1941 - 1947. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M O'Sullivan and M R Bennett Gene therapy for coronary restenosis: is the enthusiasm justified? Heart, November 1, 2001; 86(5): 491 - 493. [Full Text] [PDF]
|
|
|
|
 |
|
 N. E.J. West, H. Qian, T. J. Guzik, E. Black, S. Cai, S. E. George, and K. M. Channon Nitric Oxide Synthase (nNOS) Gene Transfer Modifies Venous Bypass Graft Remodeling: Effects on Vascular Smooth Muscle Cell Differentiation and Superoxide Production Circulation, September 25, 2001; 104(13): 1526 - 1532. [Abstract] [Full Text] [PDF]
|
|